C4 glomerulopathy natural history

Jump to navigation Jump to search

C4 glomerulopathy Microchapters

Complement Mediated Glomerular Disorders Main Page

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating C4 glomerulopathy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Studies

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

C4 glomerulopathy natural history On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of C4 glomerulopathy natural history

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on C4 glomerulopathy natural history

CDC on C4 glomerulopathy natural history

C4 glomerulopathy natural history in the news

Blogs on C4 glomerulopathy natural history

Directions to Hospitals Treating C4 glomerulopathy

Risk calculators and risk factors for C4 glomerulopathy natural history

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Ali Poyan Mehr, M.D. [2]; Associate Editor(s)-in-Chief: Olufunmilola Olubukola M.D.[3]

Overview

If left untreated, C4 glomerulopathy may progress to develop renal failure.

Natural History, Complications, and Prognosis

Natural History

The symptoms of C4 glomerulopathy usually start with symptoms such as proteinuria, hematuria, edema, renal insufficiency hypocomplementemia, and hypertension[1].

Complications

Common complications of C4 glomerulopathy include[2][3]:

  • Renal failure

Prognosis

Depending on the extent of the disease at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor[4].

References

  1. Appel GB, Cook HT, Hageman G, Jennette JC, Kashgarian M, Kirschfink M; et al. (2005). "Membranoproliferative glomerulonephritis type II (dense deposit disease): an update". J Am Soc Nephrol. 16 (5): 1392–403. doi:10.1681/ASN.2005010078. PMID 15800116.
  2. Garam N, Prohászka Z, Szilágyi Á, Aigner C, Schmidt A, Gaggl M; et al. (2019). "C4 nephritic factor in patients with immune-complex-mediated membranoproliferative glomerulonephritis and C3-glomerulopathy". Orphanet J Rare Dis. 14 (1): 247. doi:10.1186/s13023-019-1237-8. PMC 6839100 Check |pmc= value (help). PMID 31703608.
  3. Ali, Arshad; Schlanger, Lynn; Nasr, Samih H.; Sethi, Sanjeev; Gorbatkin, Steven M. (2016). "Proliferative C4 Dense Deposit Disease, Acute Thrombotic Microangiopathy, a Monoclonal Gammopathy, and Acute Kidney Failure". American Journal of Kidney Diseases. 67 (3): 479–482. doi:10.1053/j.ajkd.2015.10.020. ISSN 0272-6386.
  4. Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K; et al. (1993). "GeneReviews®". PMID 20301598.

Template:WHTemplate:WS